Patent Application Titled "Heterodimer Fc Polypeptide" Published Online (USPTO 20230416371).
In: Drug Week, 2024-01-19, S. 1932-1932
serialPeriodical
Zugriff:
The US Patent and Trademark Office has published a patent application titled "Heterodimer Fc Polypeptide" by inventors Hitoshi Katada and Kanako Tatsumi. The application focuses on the importance of antibodies in pharmaceuticals and their functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The inventors propose specific amino acid alterations in the Fc region of a polypeptide to enhance its Fc receptor (FcgR) binding ability, ADCC activity, and antibody-dependent cell-mediated phagocytosis (ADCP) activity. The altered polypeptide can be used as an antibody to target and damage specific cells, such as tumor cells. The patent application provides detailed claims and methods for producing and using the polypeptide. [Extracted from the article]
Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Application Titled "Heterodimer Fc Polypeptide" Published Online (USPTO 20230416371).
|
---|---|
Zeitschrift: | Drug Week, 2024-01-19, S. 1932-1932 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6440 (print) |
Schlagwort: |
|
Sonstiges: |
|